FOX CHASE CANCER CENTER
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1904-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.foxchase.org
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
- Conditions
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT05420636
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC
- Conditions
- Interventions
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT05400577
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
PHL Treatment in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05365893
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Redefining FOLFIORINOX in Older Pancreatic Cancer Patients
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT05360732
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Women's Health Communication Study
- Conditions
- Interventions
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT05359952
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT05274048
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Stanford Cancer Center, Palo Alto, California, United States
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 86
- Registration Number
- NCT05263050
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Local Consolidative Therapy in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT05062720
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT04827810
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Feasibility Bowel Dysfunction Program After Low Anterior Resection
- Conditions
- Interventions
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT04733794
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States